Lekethromycin injection and preparation method therefor

By adjusting the composition and preparation method of lycomycin injection, the problems of light instability and poor water solubility of lycomycin raw materials were solved, thus achieving stability of the injection under light conditions and comfort at the injection site.

WO2026232899A1PCT designated stage Publication Date: 2026-11-12PULIKE BIOLOGICAL ENG INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/078029
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-02-09
Publication Date
2026-11-12

Smart Images

  • Figure CN2026078029_12112026_PF_FP_ABST
    Figure CN2026078029_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a lekethromycin injection and a preparation method therefor. The lekethromycin injection comprises the following components: 1 w / v% to 10 w / v% of lekethromycin, 0.5 w / v% to 5 w / v% of a solubilizer, and 10 v / v% to 60 v / v% of an organic solvent, with the balance being water for injection. The pH value of the system is 3.5-5.0. The organic solvent is propylene glycol. The lekethromycin injection has good photostability and solves the problem of the active pharmaceutical ingredient lekethromycin having poor solubility in water.
Need to check novelty before this filing date? Find Prior Art

Description

Lecomycin Injection and its Preparation Method Cross-references to related applications This application claims priority to Chinese Patent Application No. 2025105799663, filed on May 7, 2025, entitled "Lycomycin Injection and Preparation Method Thereof", the entire contents of which are incorporated herein by reference. Technical Field

[0001] This application relates to the field of pharmaceutical technology, specifically providing a lecomycin injection and its preparation method. Background Technology

[0002] Swine respiratory disease syndrome (SRS) is caused by a variety of pathogens. Its characteristics include slow growth in finishing pigs, reduced feed conversion rate, anorexia, fever, coughing, and difficulty breathing. Swine respiratory disease not only has a high mortality rate, but the growth of surviving individuals is also affected, prolonging the time to market. Some infected pigs may even become runts. Some pathogens can also lead to decreased reproductive capacity in pigs. Pathogen infection is the main cause of swine respiratory disease. There are 15 common pathogens associated with swine respiratory diseases, including bacteria, viruses, mycoplasma, and parasites. Bacterial swine respiratory diseases have become one of the main causes of harm to the pig farming industry.

[0003] Pasteurella multocida infection (swine pneumonia) is a significant respiratory disease in pigs, characterized by high morbidity, severe damage, and wide spread, causing substantial economic losses to the pig farming industry. Currently, there is no effective vaccine for preventing swine respiratory diseases caused by pathogens such as Pasteurella multocida; treatment primarily relies on medication.

[0004] Macrolide antibiotics are effective against both Gram-positive and Gram-negative bacteria, especially against mycoplasma, chlamydia, Legionella, spirochetes, and rickettsia. Therefore, macrolide antibiotics play an irreplaceable role in veterinary clinical treatment of respiratory diseases in livestock and poultry.

[0005] Lecomycin is a macrolide antibiotic independently developed by Pulike Biotechnology Co., Ltd. Its chemical name is: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-{[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-[(cyclopropylamino)methyl]-α-L-ribopyranosyl]oxy}-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-7-azacyclopentadecan-15-one, and its structural formula is as follows:

[0006]

[0007] Lycomycin contains three basic amino groups in its chemical structure, giving it a high positive charge and strong electronegativity in solution. This electrostatic charge enhances the drug's ability to penetrate the extracellular lipopolysaccharide layer, thus facilitating its penetration of the outer membrane of Gram-negative bacteria and resulting in better bactericidal effects against them. The introduction of a cyclopropylamine group at the 4-position of the α-L-nucleopyranose group in lycomycin enhances its lipid solubility, increases its binding capacity, prolongs its duration of action, and reduces its toxicity.

[0008] The antibacterial mechanism of lycomycin is mainly through binding to the 23S ribosomal RNA in the 50S ribosomal subunit of bacterial ribosomes, inhibiting the transpeptidation process of pathogens and blocking the synthesis and elongation of peptide chains during protein synthesis, thereby inhibiting pathogen synthesis. Lycomycin can accumulate in target tissues such as neutrophils and alveolar macrophages, and is subsequently released slowly, thus maintaining an effective drug concentration for a relatively long time, exhibiting a long-lasting effect. Due to its lung-targeting accumulation pharmacokinetic characteristics, it is beneficial for the prevention and treatment of respiratory diseases in clinical practice, and a good therapeutic effect can be achieved after a single dose.

[0009] Based on the physicochemical and biological properties of lycomycin raw material, preparing it into an injection is more conducive to its clinical application. However, lycomycin raw material is sensitive to light and is prone to degradation under light conditions. Therefore, it is essential to study the formulation and preparation method to obtain a stable lycomycin injection solution.

[0010] In view of the above, this application is hereby submitted. Summary of the Invention

[0011] One of the purposes of this application is to provide lycomycin injection and its preparation method to solve the technical problem of poor light stability of lycomycin raw materials in the prior art.

[0012] To achieve the above objectives, this application addresses the following technical problem:

[0013] A lycomycin injection solution comprising the following components: lycomycin 1 w / v% to 10 w / v, cosolvent 0.5 w / v% to 5 w / v, organic solvent 10 v / v% to 60 v / v, with the balance being water for injection, pH 3.5 to 5.0; wherein the organic solvent is propylene glycol.

[0014] Further, the co-solvent includes at least one selected from citric acid, succinic acid, tartaric acid, and malic acid. Preferably, the co-solvent is citric acid or succinic acid.

[0015] Furthermore, the lycomycin injection comprises the following components: lycomycin 5 w / v, citric acid 2.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0016] Furthermore, the lycomycin injection comprises the following components: lycomycin 5 w / v, succinic acid 2.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0017] Furthermore, the lycomycin injection also includes an antioxidant of 0.1 w / v% to 1 w / v.

[0018] Furthermore, the antioxidant is thioglycerol.

[0019] Furthermore, the thioglycerol is 0.5 w / v%.

[0020] Furthermore, the lycomycin injection comprises the following components: lycomycin 1 w / v, citric acid 0.5 w / v, thioglycerol 0.1 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0021] Furthermore, the lycomycin injection comprises the following components: lycomycin 10 w / v, citric acid 5 w / v, thioglycerol 1 w / v, propylene glycol 60 v / v, and the balance being water for injection, pH 4.0.

[0022] The method for preparing the above-mentioned lycomycin injection is characterized in that an organic solvent, an antioxidant, and a co-solvent are added sequentially to water for injection and mixed well, then lycomycin is added and mixed well, the pH is adjusted, and the volume is brought to a final consistency to obtain the lycomycin injection.

[0023] Compared with the prior art, the technical effects of this application are as follows:

[0024] The lycomycin injection of this application has good stability under light, reducing the requirements for packaging, storage conditions and use environment; it solves the problem of poor water solubility of lycomycin raw material, and uses a water-soluble solvent, which has less irritation to the injection site. Attached Figure Description

[0025] The various technical features of this application and their relationships will be further explained below with reference to the accompanying drawings. The drawings are exemplary; some technical features are not shown to scale, and some drawings may omit technical features commonly used in the art to which this application pertains that are not essential for understanding and implementing this application, or additionally show technical features that are not essential for understanding and implementing this application. In other words, the combination of various technical features shown in the drawings is not intended to limit this application. Furthermore, throughout this application, the same reference numerals refer to the same things. Specific descriptions of the drawings are as follows:

[0026] Figure 1 is the HPLC chromatogram of related substances in solvent system 1 sample in Example 1 (day 0);

[0027] Figure 2 is the HPLC chromatogram of related substances in sample 3 of solvent system in Example 1 (day 0);

[0028] Figure 3 is the HPLC chromatogram of related substances in solvent system 2 of Example 1 (day 0);

[0029] Figure 4 is the HPLC chromatogram of related substances of lycomycin raw material in Example 1 (day 0). Detailed Implementation

[0030] To enable those skilled in the art to better understand the technical solutions of this application, the technical solutions described in this application will be further described in detail below with reference to specific embodiments.

[0031] In this application, terms such as "further," "even more," and "particularly" are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this invention.

[0032] In this application, "preferred," "preferred," and "ideal" refer to options that are optional, meaning they are selected from either "with" or "without." If multiple "preferred" options appear in a technical solution, unless otherwise specified and there are no contradictions or mutual constraints, each "preferred" option is independent.

[0033] In this application, the terms "multiple", "various", "multiple times", "multi-dimensional", etc., unless otherwise specified, refer to a quantity greater than or equal to 2. For example, "one or more" means one or more than or equal to two.

[0034] This application provides a lycomycin injection solution comprising the following components: lycomycin 1 w / v% to 10 w / v, cosolvent 0.5 w / v% to 5 w / v, organic solvent 10 v / v% to 60 v / v, and the balance being water for injection, pH 3.5 to 5.0; wherein the organic solvent is propylene glycol.

[0035] The content of lycomycin may be, but is not limited to, 1 w / v%, 2 w / v%, 3 w / v%, 4 w / v%, 5 w / v%, 6 w / v%, 7 w / v%, 8 w / v%, 9 w / v%, or 10 w / v%; the content of the solubilizer may be, but is not limited to, 0.5 w / v%, 1 w / v%, 1.5 w / v%, 2 w / v%, 2.5 w / v%, 3 w / v%, 3.5 w / v%, 4 w / v%, or 4 w / v%. 5 w / v% or 5 w / v%; the content of organic solvent may be, but is not limited to, 10 v / v%, 15 v / v%, 20 v / v%, 25 v / v%, 30 v / v%, 35 v / v%, 40 v / v%, 45 v / v%, 50 v / v%, 55 v / v% or 60 v / v, and the pH may be, but is not limited to, 3.5, 3.7, 3.9, 4.0, 4.2, 4.4, 4.6, 4.8 or 5.0.

[0036] Propylene glycol has good compatibility with lycomycin aqueous solution and is an excellent solvent for preparing lycomycin injection.

[0037] In some embodiments, the co-solvent includes at least one selected from citric acid, succinic acid, tartaric acid, and malic acid, preferably citric acid or succinic acid. The co-solvent can both improve the solubility of lycomycin in the solvent and enhance its stability under light conditions.

[0038] In one embodiment, the lycomycin injection comprises the following components: lycomycin 5 w / v, citric acid 2.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0039] In one embodiment, the lycomycin injection comprises the following components: lycomycin 5 w / v, succinic acid 2.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0040] In some embodiments, the lycomycin injection further includes an antioxidant of 0.1 w / v% to 1 w / v%. Preferably, the antioxidant is thioglycerol, more preferably 0.5 w / v% thioglycerol. The antioxidant thioglycerol can improve the stability of the injection under high temperature conditions.

[0041] In one embodiment, the lycomycin injection comprises the following components: lycomycin 5 w / v, citric acid 2.5 w / v, thioglycerol 0.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0042] In one embodiment, the lycomycin injection comprises the following components: lycomycin 5 w / v, succinic acid 2.5 w / v, thioglycerol 0.5 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0043] In one embodiment, the lycomycin injection comprises the following components: lycomycin 1 w / v, citric acid 0.5 w / v, thioglycerol 0.1 w / v, propylene glycol 40 v / v, and the balance being water for injection, pH 4.0.

[0044] In one embodiment, the lycomycin injection comprises the following components: lycomycin 10 w / v, citrate 5 w / v, thioglycerol 1 w / v, propylene glycol 60 v / v, and the balance being water for injection, pH 4.0.

[0045] The preparation method of lycomycin injection includes the following steps:

[0046] (1) Add the organic solvent to an appropriate amount of water for injection and stir to mix well;

[0047] (2) Add the antioxidant to the above mixed solvent and stir to mix well;

[0048] (3) Add the co-solvent to the above mixed solvent and stir to dissolve;

[0049] (4) Add lycomycin and stir to dissolve;

[0050] (5) Adjust the pH to 4.0 using a pH adjuster;

[0051] (6) Dilute the injection solution with water to a final volume and stir until well mixed;

[0052] (7) Sterilize and filter to obtain.

[0053] The present application is further described below with reference to specific embodiments. The advantages and features of the present application will become clear from the description. The embodiments described are merely exemplary and do not constitute any limitation on the scope of the present application. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present application without departing from the spirit and scope of the present application, but such modifications and substitutions all fall within the protection scope of the present application.

[0054] All chemical reagents used in the embodiments of this application are of analytical grade and were purchased from Sinopharm Group.

[0055] Unless otherwise specified, the experimental methods described in this application are all conventional methods; and the biological materials described are all commercially available unless otherwise specified.

[0056] Example 1: Selection of solvent system for injection solution

[0057] (1) Determination of the solubility of lycomycin in different solvent systems

[0058] Referring to commonly used solvents for injectable preparations, water, propylene glycol, polyethylene glycol 400, and glycerol formaldehyde were selected as solvents to conduct solubility tests on lycomycin raw materials. Based on the conventional dosages of propylene glycol and polyethylene glycol 400 in injectable preparations, 40% propylene glycol aqueous solution (v / v) and 30% polyethylene glycol 400 aqueous solution (v / v) were used as solvents for the tests. The experimental method was as follows: lycomycin raw materials were taken and added to different solvent systems to prepare supersaturated solutions. These solutions were then equilibrated at a constant temperature of 25°C with shaking for 24 hours. After filtration through a filter membrane and quantitative dilution, the actual solubility of the drug in the solution was determined.

[0059] Chromatographic conditions and system suitability test: Octadecylsilane-bonded silica gel was used as the packing material; phosphate buffer (0.05 mol / L dipotassium hydrogen phosphate solution, pH adjusted to 8.2 with dilute phosphoric acid)-acetonitrile (30:70) was used as the mobile phase; the flow rate was 1.0 ml / min; the detection wavelength was 210 nm; and the column temperature was 30 ℃.

[0060] Assay: Accurately measure 1 ml of the filtrate from the saturated solutions in different solvents, dilute 10–100 times with the mobile phase to prepare the test solution. Separately, take an appropriate amount of lycomycin reference standard, dissolve and dilute it with the mobile phase to prepare a solution containing approximately 1 mg of lycomycin per ml, as the reference solution. Accurately measure 20 μl each of the reference solution and the test solution, inject them separately into the liquid chromatograph, record the chromatograms, and calculate the content of lycomycin in the test solution based on the peak area using the external standard method. Then, calculate the saturated solubility of lycomycin in different solvents.

[0061] The specific results are shown in Table 1.

[0062] Table 1 Solubility of lecomycin in different solvents

[0063] The results showed that lycomycin had low solubility in purified water, 40% propylene glycol aqueous solution, and 30% polyethylene glycol aqueous solution, all below the content specifications for injection. Appropriate solubilizers need to be added to improve the solubility of lycomycin raw materials. Lycomycin had high solubility in glycerol formaldehyde, which met the content specifications for injection.

[0064] (2) Stability study of lycomycin in different solvent systems

[0065] Lycomycin was dissolved at a concentration of 50 mg / ml in three solvents: 40% propylene glycol aqueous solution (v / v), 30% polyethylene glycol 400 aqueous solution (v / v), and glycerol formaldehyde. Because lycomycin has low solubility in 40% propylene glycol and 30% polyethylene glycol aqueous solutions, dilute hydrochloric acid was used to increase its solubility during solution preparation. The pH of the solutions was adjusted to 4.0 using dilute hydrochloric acid. The formulation is shown in Table 2.

[0066] Table 2 Sample solution formulations for different solvent systems

[0067] Preparation method of solvent system 1: Add the prescribed amount of lycomycin to an appropriate amount of glycerol formaldehyde, stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up the volume with glycerol formaldehyde, shake well, filter, and dispense to obtain the solution.

[0068] Preparation method of solvent system 2: Add the prescribed amount of propylene glycol to an appropriate amount of water for injection, stir and mix well, add the prescribed amount of dilute hydrochloric acid, then add the prescribed amount of lycomycin, stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up to volume with water for injection, shake well, filter, and dispense to obtain the solution.

[0069] Preparation method of solvent system 3: Add the prescribed amount of polyethylene glycol 400 to an appropriate amount of water for injection, stir and mix well, add the prescribed amount of dilute hydrochloric acid, then add the prescribed amount of lycomycin, stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up to volume with water for injection, shake well, filter, and dispense to obtain the solution.

[0070] Samples prepared in each solvent system were placed under strong light irradiation (4500 lx ± 500 lx) for 10 days to examine changes in properties, related substances, and content, and compared with the results of the raw material drug test.

[0071] Content determination method:

[0072] Chromatographic conditions and system suitability test: Octadecylsilane-bonded silica gel was used as the packing material; phosphate buffer (0.05 mol / L dipotassium hydrogen phosphate solution, pH adjusted to 8.2 with dilute phosphoric acid)-acetonitrile (30:70) was used as the mobile phase; the flow rate was 1.0 ml / min; the detection wavelength was 210 nm; and the column temperature was 30 ℃.

[0073] Assay: Accurately weigh an appropriate amount of sample, dissolve and dilute it with the mobile phase to prepare a solution containing approximately 1.0 mg of lycomycin per ml. Use this solution as the test solution. Accurately measure 20 μl and inject it into the liquid chromatograph, recording the chromatogram. Separately, take an appropriate amount of lycomycin reference standard and determine it using the same method. Simultaneously determine the relative density of the product and convert the sample weight to milliliters. Calculate the density using the external standard method based on peak area.

[0074] Related substances determination methods:

[0075] Take 1 ml of sample and place it in a 10 ml volumetric flask. Add 1 ml of 3.46 g / L ammonium dihydrogen phosphate solution-acetonitrile (62.5:37.5) (adjust the pH to 10.2 with ammonia solution). Then add diluent [1.73 g / L ammonium dihydrogen phosphate solution (adjust the pH to 10.0 with ammonia solution)-methanol-acetonitrile (35:35:30)] to the mark and shake well to obtain the test solution. Accurately measure 1 ml of the test solution and place it in a 100 ml volumetric flask. Dilute to the mark with the above diluent and shake well to obtain the control solution. The determination was performed using high-performance liquid chromatography (HPLC). Octadecylsilane-bonded silica gel was used as the stationary phase. Mobile phase A consisted of 0.01 mol / L dipotassium hydrogen phosphate solution (pH adjusted to 8.0 with 10% phosphoric acid solution) - methanol - acetonitrile (920:20:60), and mobile phase B consisted of 0.01 mol / L dipotassium hydrogen phosphate solution (pH adjusted to 8.0 with 10% phosphoric acid solution) - methanol - acetonitrile (220:195:585). The column temperature was 40℃, and linear gradient elution was performed according to the program in Table 3. The flow rate was 1.0 mL / min, and the detection wavelength was 210 nm. 20 μL of each of the test solution and control solution were accurately injected into the HPLC system, and the chromatograms were recorded.

[0076] Table 3 Gradient elution program

[0077] The experimental results are shown in Table 4 and Figure 1-4.

[0078] Table 4. Results of light irradiation tests on samples of lycomycin in different solvent systems.

[0079] The results showed that the related substances in the sample prepared from lycomycin with glycerol formaldehyde and polyethylene glycol 400 aqueous solution increased significantly after 0 days compared to the raw material, indicating that the solvent system of glycerol formaldehyde and polyethylene glycol 400 aqueous solution is unfavorable to the stability of lycomycin. The related substances in the sample prepared from lycomycin with propylene glycol aqueous solution did not change significantly after 0 days compared to the raw material, but after 10 days under light exposure (4500 lx ± 500 lx), the related substances increased significantly, and the changes were basically consistent with those of the raw material. Based on the above experimental results, the compatibility of lycomycin with propylene glycol aqueous solution is better than that with glycerol formaldehyde and polyethylene glycol 400 aqueous solution. However, the propylene glycol aqueous solution system did not solve the stability problem under light exposure, and lycomycin has low solubility in propylene glycol aqueous solution. Therefore, the propylene glycol aqueous solution system is preferred, and further formulation studies will be conducted.

[0080] Example 2: Screening of Cosolvents

[0081] Succinic acid and citric acid can both be used as cosolvents in pharmaceutical preparations. The type and amount of cosolvent can affect the solubility of the active pharmaceutical ingredient, the properties of the product, and its stability. Therefore, the stability under high temperature (40℃) and light (4500lx±500lx) conditions was used as an indicator to investigate different types of cosolvents. The formulations and preparation methods of different cosolvents are shown in Table 5, and the experimental results are shown in Table 6.

[0082] Table 5. Formulations of sample solutions with different cosolvents

[0083] Preparation method of solubilizer 1: Add the prescribed amount of propylene glycol to an appropriate amount of water for injection, stir and mix well, add the prescribed amount of dilute hydrochloric acid, then add the prescribed amount of lycomycin, stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up to volume with water for injection, shake well, filter, and dispense to obtain the product.

[0084] Preparation method of solubilizer 2: Add the prescribed amount of propylene glycol to an appropriate amount of water for injection, stir and mix well, add the prescribed amount of citric acid and stir to dissolve, then add the prescribed amount of lycomycin and stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up to volume with water for injection, shake well, filter, and dispense to obtain the product.

[0085] Preparation method of solubilizer 3: Add the prescribed amount of propylene glycol to an appropriate amount of water for injection, stir and mix well, add the prescribed amount of succinic acid and stir to dissolve, then add the prescribed amount of lycomycin and stir to dissolve, adjust the pH to 4.0 with dilute hydrochloric acid, make up to volume with water for injection, shake well, filter, and dispense to obtain the product.

[0086] Table 6. Test results for samples with different cosolvents

[0087] The results showed that while dilute hydrochloric acid, citric acid, and succinic acid could all increase the solubility of lycomycin in propylene glycol aqueous solution, the stability of the samples varied significantly depending on the co-solvent used. Using citric acid and succinic acid as co-solvents not only solved the solubility problem of lycomycin raw material in propylene glycol aqueous solution, but also resulted in samples with good stability under high temperature (40℃) and light irradiation (4500 lx ± 500 lx). Compared with the raw lycomycin, the stability of the samples under light irradiation conditions was significantly improved.

[0088] Example 3: Preparation of lecomycin injection

[0089] (1) Formula and preparation method of lecomycin injection

[0090] Preparation method:

[0091] ① Add propylene glycol to 40 ml of water for injection and stir to mix well;

[0092] ② Add thioglycerin and stir to mix well;

[0093] ③ Add citric acid and stir to dissolve;

[0094] ④ Add lycomycin and stir to dissolve;

[0095] ⑤ Adjust the pH to 4.0 with dilute hydrochloric acid;

[0096] ⑥ Add water for injection to 100ml and stir to mix well;

[0097] ⑦ Sterilize and filter, then fill.

[0098] (2) Factors affecting lycomycin injection

[0099] The prepared lycomycin injection solution was placed under high temperature (40℃) and light (4500lx±500lx) conditions for 10 days, and samples were taken for testing on the 5th and 10th days.

[0100] The test results are shown in Table 7.

[0101] Table 7. Results of Experiments on Factors Affecting the Effect of Lecomycin Injection

[0102] The results showed that lycomycin was relatively stable under both high temperature (40℃) and light (4500lx±500lx) conditions, and its properties, related substances, and contents did not change significantly. Compared with sample 2 of cosolvent in Example 2, the two samples had the same stability under light conditions, but the stability of this sample was slightly better than that of sample 2 of cosolvent under high temperature conditions, indicating that the antioxidant thioglycerol can improve the stability of the sample under high temperature conditions.

[0103] Example 4: Preparation of lecomycin injection

[0104] (1) Formula and preparation method of lecomycin injection

[0105] Preparation method:

[0106] ① Add propylene glycol to 70 ml of water for injection and stir to mix well;

[0107] ② Add thioglycerin and stir to mix well;

[0108] ③ Add citric acid and stir to dissolve;

[0109] ④ Add lycomycin and stir to dissolve;

[0110] ⑤ Adjust the pH to 4.0 with dilute hydrochloric acid;

[0111] ⑥ Add water for injection to 100ml and stir to mix well;

[0112] ⑦ Sterilize and filter, then fill.

[0113] (2) Factors affecting lycomycin injection

[0114] The prepared lycomycin injection solution was placed under high temperature (40℃) and light (4500lx±500lx) conditions for 10 days, and samples were taken for testing on the 5th and 10th days.

[0115] The test results are shown in Table 8.

[0116] Table 8. Results of the experiment on influencing factors of lycomycin injection.

[0117] The results showed that lycomycin was relatively stable under high temperature (40℃) and light (4500lx±500lx) conditions, and its properties, related substances, and contents did not change significantly.

[0118] Example 5: Preparation of lecomycin injection

[0119] (1) Formula and preparation method of lecomycin injection

[0120] Preparation method:

[0121] ① Add propylene glycol to 20 ml of water for injection and stir to mix well;

[0122] ② Add thioglycerin and stir to mix well;

[0123] ③ Add succinic acid and stir to dissolve;

[0124] ④ Add lycomycin and stir to dissolve;

[0125] ⑤ Adjust the pH to 4.5 with dilute hydrochloric acid;

[0126] ⑥ Add water for injection to 100ml and stir to mix well;

[0127] ⑦ Sterilize and filter, then fill.

[0128] (2) Factors affecting lycomycin injection

[0129] The prepared lycomycin injection solution was placed under high temperature (40℃) and light (4500lx±500lx) conditions for 10 days, and samples were taken for testing on the 5th and 10th days.

[0130] The test results are shown in Table 9.

[0131] Table 9. Results of Experiments on Factors Affecting the Effect of Lecomycin Injection

[0132] The results showed that lycomycin was relatively stable under high temperature (40℃) and light (4500lx±500lx) conditions, and its properties, related substances, and contents did not change significantly.

[0133] Unless otherwise defined, all technical and scientific terms used throughout this application have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. In case of any inconsistency, the meaning as stated in this application or derived from the content described herein shall prevail. Furthermore, the terminology used in this description is for the purpose of describing embodiments of this application only and is not intended to limit this application.

[0134] Note that the above are merely preferred embodiments and the technical principles employed in this application. Those skilled in the art will understand that this application is not limited to the specific embodiments described herein, and various obvious changes, readjustments, and substitutions can be made without departing from the scope of protection of this application. Therefore, although this application has been described in detail through the above embodiments, this application is not limited to the above embodiments. Many other equivalent embodiments may be included without departing from the technical concept of this application, all of which fall within the scope of protection of this application.

Claims

1. A leucomycin injection, characterized by, The lecomycin injection comprises the following components: lecomycin 1w / v%~10w / v%, cosolvent 0.5w / v%~5w / v%, organic solvent 10v / v%~60v / v%, and the rest is water for injection, pH 3.5~5.0; the organic solvent is propylene glycol.

2. The leucomycin injection according to claim 1, characterized by, The cosolvent comprises at least one of citric acid, succinic acid, tartaric acid and malic acid; preferably, the cosolvent is citric acid or succinic acid.

3. The leucomycin injection according to claim 1, characterized by, The lecomycin injection comprises the following components: lecomycin 5w / v%, citric acid 2.5w / v%, propylene glycol 40v / v%, and the rest is water for injection, pH 4.

0.

4. The leucomycin injection according to claim 1, characterized by, The lecomycin injection comprises the following components: lecomycin 5w / v%, succinic acid 2.5w / v%, propylene glycol 40v / v%, and the rest is water for injection, pH 4.

0.

5. The leucomycin injection according to any one of claims 1 to 4, characterized by, The lecomycin injection further comprises antioxidant 0.1w / v%~1w / v%.

6. The leucomycin injection according to claim 5, characterized by, The antioxidant is thio-glycerol.

7. The leucomycin injection according to claim 6, characterized by, The thio-glycerol is 0.5w / v%.

8. The leucomycin injection according to claim 5, characterized by, The lecomycin injection comprises the following components: lecomycin 1w / v%, citric acid 0.5w / v%, thio-glycerol 0.1w / v%, propylene glycol 40v / v%, and the rest is water for injection, pH 4.

0.

9. The leucomycin injection according to claim 5, characterized by, The lecomycin injection comprises the following components: lecomycin 10w / v%, citric acid 5w / v%, thio-glycerol 1w / v%, propylene glycol 60v / v%, and the rest is water for injection, pH 4.

0.

10. The method of preparing the leucomycin injection according to any one of claims 1 to 9, characterized by, The organic solvent, antioxidant and cosolvent are sequentially added in water for injection, mixed, then lecomycin is added and mixed, the pH is adjusted, and the lecomycin injection is obtained.